News | PET-CT | August 04, 2021

The market is projected to reach to $3 billion by the end of 2028

PET, PET imaging, PET-CT, FDG PET, PET cancer assessment, pet scanner, nuclear imaging, molecular imaging

A PET-CT head and neck cancer scan showing various image reconstructions. The top left image is the separate CT scan showing the anatomy. The top right scan shows the fused PET and CT scans with false color added to help interpret the image. The bottom left scan is an initial FDG PET image showing tracer hot spots in the neck and a lymph node in the right jaw due to cancer. The right bottom image is a delayed enhancement scan showing tracer uptake over time, with normal hot spots in the bladder, kidneys, testicles and brain, which normally have higher metabolic activity. The low-grade gray shading of the anatomy is due to the normal cellular metabolism uptake of the FDG throughout the body. 


August 4, 2021 — PET/CT systems are expected to continue to incorporate the highest clinical performance of PET as well as computed tomography (CT), and further evolve in parallel with these modalities for a long period. Constant developments in the radiopharmaceuticals used by PET/CT systems and increased government support for the research and development of these radiopharmaceuticals for medical imaging is expected to propel the PET/CT systems market during the forecast period.

According to the latest research by PMR, the global PET/CT systems market is expected to account for more than 3.0 billion US$ in terms of value, by the end of 2028. The PET/CT systems report also projects a significant growth potential, with an average Y-O-Y growth rate pegged at 6.2% through 2028.

PET/CT Systems Market: Dynamics

High capital investments are expected to be recovered by increased medical efficacy and patient throughput, leading to a decrease in the effective cost per image. According to various research studies, excluding additional costs, the usage of PET/CT systems is cost-efficient as these systems help avoid additional invasive procedures or imaging examinations. According to the president of Clinical Radiologists, Springfield, a new PET/CT systems costs around US$ 2 Million and a high-end CT system costs around $1 Million. It costs around $600,000 – 700,000 less to buy Biograph mCT, as compared to purchasing 2 different high-end systems.

Moreover, the device can be stored in a single room. Furthermore, PET is quite a lengthy procedure that requires transmission as well as emission scans. The fusion image by PET/CT systems was projected to result in time saving for almost about 20-30 minutes per patient, which led to a 40% increase in patient output. According to a research study published by National Center for Biotechnology Information, the U.S., the metastases found in 16% of cancer patients, which was initially deemed resectable, led to cost savings amounting to US$ 1,066 per patient with the usage of PET/CT systems.

PET/CT Systems Market: Segmentation

PMR has segmented the global PET/CT systems market based on the product type, isotopes, modality, applications, end use and region. The PET/CT systems market by product type is segmented into low-range slice PET/CT systems (>20), middle range-slice PET/CT systems (21-64), high-range slice PET/CT systems (<64). By isotopes, the market for PET/CT systems is segmented into Flurodeoxyglucose, 18 F Sodium Fluoride, 62 Cu ATSM, FMISO, Thallium, Gallium, and others. By modality, the PET/CT systems market is segmented into fixed PET/CT systems and mobile PET/CT systems.

By application, the PET/CT systems market is segmented into oncology, cardiology, neurology, and others. By end use, the PET/CT systems market is segmented into hospitals, diagnostic centers, cancer research centers, and specialty clinics. The PET/CT systems market has been analyzed across all the regions of North America, Latin America, Europe, South Asia, East Asia, Oceania, and the Middle East & Africa. 

PET/CT Systems Market: Competition Tracking

The PET/CT systems report tracks some of the key companies operating in the PET/CT systems market, which include Siemens AG; Hitachi, Ltd.; Koninklijke Philips N.V.; Canon, Inc.; General Electric Company; MinFound Medical Systems Co., Ltd.; and Neusoft Corporation.

For more information: www.persistencemarketresearch.com

Related PET/CT content:

How Digital PET/CT Can Improve Clinical Care

Digital PET Balances Scan Time and Resolution

What Precision Means To PET

Digital Technology Pushes PET In New and Old Directions

 


Related Content

News | Computed Tomography (CT)

At the annual AHRA (American Healthcare Radiology Administrators) conference in Orlando, Florida, Bayer announced an ...

Time August 09, 2024
arrow
News | Computed Tomography (CT)

SPONSORED CONTENT — Fujifilm’s latest CT technology brings exceptional image quality to a compact and user- and patient ...

Time August 06, 2024
arrow
News | Radiology Business

July 31, 2024 — The American Registry of Radiologic Technologists (ARRT) announced the three Registered Technologists (R ...

Time July 31, 2024
arrow
Feature | Computed Tomography (CT) | By Melinda Taschetta-Millane

In the ever-evolving landscape of medical imaging, computed tomography (CT) stands out as a cornerstone technology ...

Time July 30, 2024
arrow
News | Prostate Cancer

July 30, 2024 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time July 30, 2024
arrow
Videos | Radiology Business

Find actionable insights to achieve sustainability and savings in radiology in this newest of ITN’s “One on One” video ...

Time July 30, 2024
arrow
Feature | Radiology Business | By Christine Book

Across the healthcare industry, and, notably, throughout the radiology community in just the past few years, the focus ...

Time July 26, 2024
arrow
Feature | Mobile C-Arms | By Melinda Taschetta-Millane

Mobile C-arms continue to revolutionize medical imaging, offering versatility, mobility and real-time visualization ...

Time July 26, 2024
arrow
News | Radiology Business

July 25, 2024 — Immunis, Inc., a clinical-stage biotech developing groundbreaking secretome therapeutics for age and ...

Time July 25, 2024
arrow
News | Radiopharmaceuticals and Tracers

July 25, 2024 — NorthStar Medical Radioisotopes, LLC and BWXT Medical Ltd., a subsidiary of BWX Technologies, Inc ...

Time July 25, 2024
arrow
Subscribe Now